Q1 2025 Earnings Call Transcript February 13, 2025 Applied DNA Sciences, Inc. misses on earnings expectations. Reported EPS is $-0.56 EPS, expectations were $-0.32. Operator: Good day, and welcome to ...

STONY BROOK, NY - Applied DNA Sciences Inc . (NASDAQ:APDN), a company specializing in testing laboratories currently trading at $0.17 per share with a market capitalization of $8.89 million, reported ...

And the news about BitGo: a web3 asset custodian trust launching their IPO to go public, did not go down well with some ...

In December 2024, the Company announced a strategic restructuring of its business operations, including the potential divestiture of its DNA Tagging and Security Products and Services ("DNA Tagging") ...

When researchers looked at the production records of calves in commercial operations, they found that, on average, calves ...

NHL commissioner Gary Bettman confirmed that the 2028 World Cup of Hockey will be held. He called for cities to submit bids ...

SAO PAULO (Reuters) -Brazil's agricultural research agency Embrapa, which helped turn the country into a leading grains ...

上证报中国证券网讯2月12日晚间， 德展健康 （ 000813 ）发布公告称，公司参股公司北京东方略生物医药科技股份有限公司于近日收到国家药品监督管理局 (NMPA)核准签发的《药物临床试验批准通知书》，批准了其与美国Inovio Pharmaceuticals,Inc.合作研发的VGX-3100项目。

资料显示，Inovio公司创立于1979年，目前已有42年历史，主要从事HPV、癌症、传染病相关的DNA药物研发，合作伙伴包括东方略、阿斯利康、比尔和梅琳达.盖茨基金会和流行病防范创新联盟 (CEPI)等。 据公告披露，VGX-3100是东方略与Inovio公司在DNA免疫治疗领域的重点合作开发项目，用于治疗由人类乳头状瘤病毒 ...

根据AI大模型测算海利生物后市走势。短期趋势看，该股当前无连续增减仓现象，主力趋势不明显。主力没有控盘。中期趋势方面，上方有一定套牢筹码积压。近期该股获筹码青睐，且集中度渐增。舆情分析来看，目前市场情绪极度悲观。